Re­turn of the megarounds; Nvidia’s AI pitch to biotech; Bay­er’s shake­up reach­es the top; As­traZeneca buys in­to ra­dio­phar­ma; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In case you missed it, we launched our lat­est newslet­ter this week. Post-Hoc, as we call it, is a week­ly(ish) piece of analy­sis that fol­lows big news, an in­sight from the jour­nal­ist who broke the sto­ry, or a per­spec­tive that’s cru­cial to un­der­stand­ing events shap­ing bio­phar­ma and health­care. Learn more and sign up for it here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER